Relburn-Metabolomics, Inc.
Westfield, NJ 07090

Relburn-Metabolomics Files Fourth Patent for its Anti-Gout Drug Portfolio

Initial Portfolio Patent Receives U.S. Notice of Allowance

Westfield, NJ – August 1, 2016 -- Relburn-Metabolomics, Inc. announced that the Company has filed a fourth patent application for its anti-gout drug portfolio. Similar in scope to earlier applications from this portfolio, the new patents -- filed initially in the U.S. -- have also been filed worldwide. These applications include claims on novel drug structures and compositions, dosing ranges, methods of use, and disease treatments. In parallel, the Company also announced that it has received a Notice of Allowance for the first U.S. patent in the portfolio (Application No. 14/078,668), which was filed in 2013 and related to initial compound discoveries from this family of drugs.

“The Notice of Allowance is especially important, since it indicates our initial work -- upon which subsequent and derivative discovery work has been based -- is comprised of structurally novel compounds”, said Dr. Raymond P. Warrell, Jr. MD, Chief Executive Officer. “The Company expects to declare a lead compound for its initial clinical work in the anti-gout program during the second half of this year.”

About Relburn-Metabolomics

Relburn is an emerging life-science company focused on improving health for patients with metabolic and inflammatory diseases. Relburn’s lead program is focused on the development of transformational therapy for chronic gout – a disease whose prevalence is doubling every 10 years and currently afflicts 16 million subjects in major markets. Gout is caused by excess uric acid (UA) in blood and connective tissues that leads to exquisitely painful and destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease. Standard treatment seeks to either reduce production or increase excretion of UA. Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on *both* UA production *and* excretion. Targeting enzymes that mediate these activities, Relburn compounds are markedly more potent than standard drugs and have demonstrated exceptional clinical activity.

Gout treatment is focused on reducing UA to a target serum level less than 6.0 mg/dL that is known to be beneficial. The Relburn prototype drug – tested in more than 350 patients -- showed that serum UA routinely dropped to less than 1.0 mg/dL, even at low doses. With this “clinical proof-of-concept”, Relburn has synthesized compounds to

further enhance clinical activity and reduce potential side-effects. This drug library is covered by patent applications that are exclusively owned by the Company. Relburn believes its drugs may replace current 1st-line treatments for gout, thereby leading to meaningful improvement in patient well-being.

Further information about Relburn-Metabolomics, Inc. can be accessed at: www.relburn.com.

This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets, or future developments, and are not statements of historical fact. The words "potentially", "anticipates", "believes", "expects", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.

Relburn company information: info@relburn.com

SOURCE: Relburn-Metabolomics® Inc.